Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: imagingglioblastomaconcurrentradiotherapybrain
  Phrases that lowered it: effectperiodmalethe studyoral
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 8.2% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 65 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 145 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme NCT00915694 · started 2009 · scored riskier than 60% of active trials terminated
• A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma NCT01020292 · started 2009 · scored riskier than 76% of active trials completed
• A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme NCT02853565 · started 2016 · scored riskier than 40% of active trials completed
• ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme NCT00770471 · started 2009 · scored riskier than 79% of active trials completed
• Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma NCT03782415 · started 2018 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.